KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Current Assets (2018 - 2025)

Aurinia Pharmaceuticals' Current Assets history spans 7 years, with the latest figure at $492.0 million for Q4 2025.

  • For Q4 2025, Current Assets rose 10.16% year-over-year to $492.0 million; the TTM value through Dec 2025 reached $492.0 million, up 10.16%, while the annual FY2025 figure was $492.0 million, 10.16% up from the prior year.
  • Current Assets reached $492.0 million in Q4 2025 per AUPH's latest filing, up from $438.7 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $513.3 million in Q4 2021 to a low of $329.2 million in Q3 2021.
  • Average Current Assets over 5 years is $426.4 million, with a median of $425.6 million recorded in 2023.
  • The largest YoY upside for Current Assets was 39.63% in 2022 against a maximum downside of 13.79% in 2022.
  • A 5-year view of Current Assets shows it stood at $513.3 million in 2021, then decreased by 13.79% to $442.5 million in 2022, then decreased by 4.01% to $424.8 million in 2023, then grew by 5.13% to $446.6 million in 2024, then increased by 10.16% to $492.0 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Current Assets are $492.0 million (Q4 2025), $438.7 million (Q3 2025), and $409.0 million (Q2 2025).